News dal mondo
29
Apr
US GDUFA IV Talks Reach Tentative Agreement; America First Application Fee Waiver Added
US FDA GDUFA Reauthorization performance goals and program enhancements Riscal years 2023-2027 - Meeting 23 giugno 2026 [Federal Register Volume 91, Issue 72 - April 15, 2026]
US FDA GDUFA Reauthorization performance goals and program enhancements Riscal years 2023-2027 - Meeting 23 giugno 2026
[Federal Register Volume 91, Issue 72 - April 15, 2026]
30
AIFA pubblica il Terzo Position Paper sui farmaci biosimilari
È online il terzo Position Paper AIFA sui farmaci biosimilari. L’aggiornamento del documento...
28
Sun Pharma compra Organon
Sun Pharmaceutical Industries ha firmato un accordo definitivo per acquisire Organon &...
27
US QMM: Participants scored well on commitment to quality, lower on advanced manufacturing
Pharmaceutical companies participating in the US Food and Drug Administration (FDA) Quality Maturity...
23
Top Drugs at Risk of Supply Shortages
Nearly half of 100 vulnerable medicines have at least one key starting material sourced exclusively...
le ultime news
04 Mar
ECHA’s Risk Assessment Committee adopts its opinion on PFAS restriction proposal
27 Feb
US FDA Announces the 2026 QMM Prototype Assessment Protocol Evaluation Program
Quantum computing nelle life sciences: a Milano un convegno per l’industria farmaceutica
24 Feb
Industry clamors for clearer guidance on transition to ICH M4Q(R2)
23 Feb
USA . La Corte Suprema boccia i dazi globali di Trump: cosa cambia e perché il pharma resta nel mirino
20 Feb
NerPharma acquistata da un colosso farmaceutico francese
Generic industry against giving fee breaks to firms setting up operations in the US
US FDA: svolta storica: basterà un solo studio registrativo per approvare i nuovi farmaci
<<<5 6 7>>>
